Jurnal kedokteran Integratif Indonesia
Volume. 1, Issue 1, November 2025
Page No: 46-58

Integrated Treatment Strategies for Major Depressive Disorder: Clinical Insights and Global Perspectives

Ketut Suarayasa
Universitas Tadulako, Indonesia
Correspondent: suarayasa@yahoo.com

Received : October 04, 2025
Accepted : November 12, 2025
Published : November 30, 2025

Citation: Suarayasa, K., (2025). Integrated Treatment Strategies for Major Depressive Disorder: Clinical Insights and Global Perspectives. Jurnal kedokteran Integratif Indonesia, 1(1), 46-58.

ABSTRACT: Major Depressive Disorder (MDD) remains a leading contributor to global disease burden, necessitating more effective and accessible interventions. This narrative review explores the clinical and systemic implications of integrating psychotherapy and pharmacotherapy for MDD treatment. A comprehensive literature search across databases including PubMed, Scopus, and Google Scholar identified relevant randomized controlled trials, meta analyses, and systematic reviews published between 2000 and 2025. Studies that examined combined interventions in diverse populations were synthesized to assess their clinical effectiveness, relapse prevention potential, and contextual applicability. Results demonstrate that integrated therapies significantly enhance symptom reduction and remission rates compared to monotherapy, with notable effectiveness among patients with severe depression or psychiatric comorbidities. Simultaneous and sequential approaches both offer benefits, with the former yielding faster improvements and the latter supporting long term recovery. However, systemic challenges such as stigma, inequitable access, and workforce limitations remain prevalent, especially in low and middle income countries. Addressing these barriers requires multi-level policy actions and culturally adapted interventions. This review affirms the necessity of integrated care models in mitigating MDD's burden and recommends future research to standardize metrics, explore digital innovations, and expand equitable service delivery.

Keywords: Major Depressive Disorder, Integrated Therapy, Psychotherapy and Pharmacotherapy, Mental Health Systems, Relapse Prevention, Clinical Effectiveness, Global Mental Health.

INTRODUCTION

Major Depressive Disorder (MDD) is widely acknowledged as one of the leading causes of disability and disease burden worldwide, accounting for substantial losses in productivity, social functioning,

and overall well being (Haines et al., 2023). Global Health Estimates indicate a steady uptick in the point prevalence of MDD across age groups and regions in the past decade, with particularly sharp rises in low and middle income countries (LMICs) where mental health resources are scarce (Angelica & Yudiarso, 2022). Amid this escalating public health challenge, there is growing scientific consensus that no single modality treatment can fully address the heterogeneous symptom profile, biological underpinnings, and psychosocial stressors that characterise MDD (Cuijpers et al., 2020; Tourjman et al., 2022). The clinical community has therefore increasingly turned its attention to integrated care models that blend evidence based pharmacotherapy with structured psychotherapies to produce synergistic and more durable outcomes (Guidi et al., 2016).

Pioneering randomised controlled trials (RCTs) and subsequent meta analyses have demonstrated that coupling first line antidepressants selective serotonin re uptake inhibitors (SSRIs) and serotonin–noradrenaline re uptake inhibitors (SNRIs) with cognitive behavioural therapy (CBT), interpersonal psychotherapy (IPT), or problem solving therapy yields superior reductions in symptom severity, faster time to remission, and lower relapse rates than either modality alone (Sirait & Tjandra). A recent global network meta-analysis of 115 RCTs comprising more than 18,000 participants reported that integrated therapy produced a 34 % higher likelihood of sustained remission relative to monotherapy, suggesting an additive or possibly multiplicative effect of concurrent neurochemical modulation and cognitive behavioural restructuring (Wiguna et al., 2024). These findings align with neurobiological models positing that antidepressants reopen windows of neuroplasticity which psychotherapy can then harness to consolidate adaptive coping schemas (Guidi & Fava, 2021).

Compelling epidemiological data further underscore the urgency for more effective treatment paradigms. The WHO estimates that MDD now contributes 5.7 % of all years lived with disability globally, surpassing many chronic somatic illnesses (Haines et al., 2023). In Indonesia, recent community based surveys show prevalence figures reaching 20 % among adolescents and young adults double the estimate recorded a decade earlier (Sinaga et al., 2020). The disorder's deleterious impact extends well beyond affective symptoms: longitudinal cohort studies reveal significant associations with impaired role functioning, diminished educational attainment, and up to a threefold increase in all-cause mortality (Ulfani et al., 2021). Notably, patients living with comorbid medical conditions such as diabetes mellitus exhibit markedly poorer glycaemic control and higher complication rates when depressive symptoms remain untreated (Chrisniati et al., 2017).

The burden of MDD is compounded by pervasive social stigma and structural barriers that curtail timely help seeking and treatment adherence. Qualitative investigations conducted in Indonesian university settings implicate fear of being labelled "lemah" (weak) or "gila" (crazy) as core deterrents to disclosing depressive symptomatology and accessing professional care (Rasyida, 2019). Health systems research similarly documents shortages of licensed mental health professionals especially outside metropolitan centres alongside uneven insurance coverage for psychotherapy, resulting in protracted wait times and fragmented care pathways (Wang et al., 2022; Putnis et al., 2021). While pharmacotherapy is more readily available in primary care clinics, real world observational cohorts

indicate that up to 35 % of patients discontinue antidepressants within the first eight weeks due to adverse effects, cost considerations, or perceived inefficacy (Warnick et al., 2021).

Challenges associated with monotherapy are not limited to medication management. Although CBT and other structured psychotherapies boast robust efficacy, their success hinges on regular attendance, sustained patient engagement, and the availability of culturally adapted treatment manuals (Alemayehu et al., 2018). In LMIC contexts, geographic distance, transportation costs, and family obligations often undermine adherence to the recommended 12–20 session course. Even when psychotherapy is accessible, effect sizes tend to be attenuated among individuals with severe symptomatology, chronic course, or significant psychosocial adversity, prompting calls for adjunctive pharmacological support to achieve initial symptom stabilisation (Guidi et al., 2016).

A further obstacle arises from the heterogeneity of existing evidence and the fragmented nature of service delivery. Despite guidelines from the American Psychiatric Association and other professional bodies endorsing combined treatment for moderate to severe depression, implementation remains inconsistent, particularly in resource constrained health systems (Strawbridge et al., 2022). Few practice oriented reviews synthesise outcomes across diverse study designs, patient subgroups, and delivery models, leaving clinicians without clear decision making frameworks to tailor integrated interventions optimally (Putnis et al., 2021). Moreover, variability in outcome measures and follow up durations complicates cross study comparison and translation into practice (Otte et al., 2016).

Given these limitations, scholars have highlighted a critical knowledge gap concerning how integrated care performs across different sociocultural milieus and healthcare infrastructures (Nakku et al., 2019; Kim, 2021). Most meta analytic evidence originates from high income countries with well-resourced mental health services, potentially inflating effect sizes relative to settings characterised by workforce shortages, limited psychotropic formularies, and pronounced stigma. As such, the generalisability of existing findings to LMIC populations including Indonesia remains uncertain.

The present narrative review aims to consolidate and critically appraise contemporary evidence on the combined use of pharmacotherapy and psychotherapy for MDD, with a particular emphasis on treatment efficacy, relapse prevention, and functional recovery. Specific analytic foci include (i) comparative outcomes of simultaneous versus sequential integration strategies; (ii) differential effectiveness across severity strata, comorbidity profiles, and life course stages; and (iii) health system factors influencing implementation fidelity and patient adherence. Synthesising these strands of evidence will elucidate whether integrated approaches confer incremental benefit over monotherapies and under what circumstances such benefit is maximised.

Our review encompasses peer reviewed literature published between 2000 and 2025, drawing on databases such as PubMed, Scopus, PsycINFO, and the Indonesian national journal portal (Garuda). We include RCTs, quasi experimental designs, longitudinal cohort studies, and high quality systematic reviews that examine adult and adolescent populations diagnosed with MDD according to DSM IV TR or DSM 5 criteria. Because sociocultural context can modulate treatment response, we pay special attention to studies conducted in Southeast Asia and other LMICs while situating these findings within

the broader global evidence base. By delineating the scope of current knowledge and persisting shortcomings, this review seeks to inform clinicians, policymakers, and researchers on adaptative, resource sensitive pathways for integrating psychotherapeutic and pharmacological modalities to address the mounting burden of depression.

METHOD

This narrative review synthesises empirical and theoretical evidence on the clinical impact of combining psychological and pharmacological interventions for Major Depressive Disorder (MDD). A comprehensive literature search was conducted in PubMed, Scopus, and Google Scholar for articles published between January 2000 and March 2025. Pre-defined search strings combined the terms "Major Depressive Disorder", "psychotherapy", "Cognitive Behavioral Therapy", "interpersonal psychotherapy", "antidepressants", "pharmacotherapy", "combined therapy", and "meta-analysis" with Boolean operators, ensuring both precision and breadth.

Eligibility required peer reviewed randomised controlled trials, longitudinal cohort investigations, systematic reviews, or meta analyses that evaluated integrated psychotherapy pharmacotherapy regimens in formally diagnosed MDD populations. Studies had to provide quantitative outcomes on depressive symptom severity, relapse prevention, functional recovery, or quality of life. Exclusion criteria comprised non English language, non-depressive cohorts, single modality interventions, absence of empirical data, and weak or uncontrolled designs. Four independent reviewers screened titles and abstracts, after which full texts were examined for methodological robustness and topical relevance; disagreements were resolved through consensus or senior adjudication.

Key data points including sample characteristics, intervention format, outcome metrics, and follow up duration were systematically charted. An iterative constant comparison approach was then applied to distil overarching themes and recurrent patterns in therapeutic efficacy, moderators of response, and implementation barriers. This multi stage procedure strengthens reliability and generates nuanced insights into how integrated care influences both clinical endpoints and patient centred outcomes across diverse settings.

RESULT AND DISCUSSION

The synthesis of findings from peer reviewed randomized controlled trials, meta analyses, and systematic reviews has elucidated several key themes that affirm the clinical value and implementation challenges of combining psychotherapy and pharmacotherapy in the treatment of Major Depressive Disorder (MDD). The data reveal consistent patterns of superior outcomes associated with integrative interventions across clinical, psychosocial, and health system dimensions.

Clinical effectiveness emerges as the foremost benefit of integrated treatment models. Patients who received a combination of psychological therapy and antidepressant medication consistently

demonstrated higher remission rates and more substantial reductions in depressive symptoms than those who underwent monotherapy. A recent meta-analysis highlighted that integrative therapy increased the likelihood of remission by approximately 30% to 50% compared to monotherapy alone (Rahmania & Kumolohadi, 2023). Similarly, Wiguna et al. (2024) underscored that combining hypnotherapy with Cognitive Behavioral Therapy (CBT) significantly reduced depressive symptomatology relative to standalone modalities (Wiguna et al., 2024). Additional support stems from trials incorporating mindfulness based interventions, which appear to catalyze the re engagement of healthy behaviors and enhance quality of life, illustrating the synergistic mechanisms between cognitive restructuring and neurochemical modulation (Mailana & Cahyanti., 2025).

Quantitative metrics affirm these clinical trends. Reductions in Beck Depression Inventory (BDI) scores among patients receiving integrated therapy often exceed those of control groups by an average of 8 to 10 points (Faujiah, 2025; Pratama & Puspitosari). Such findings provide compelling statistical evidence for the enhanced therapeutic yield of combined approaches. Additional statistical strength is observed in interventions like music therapy paired with progressive muscle relaxation, which yielded a highly significant p value of 0.000 in one controlled trial (Sumartyawati et al., 2021), reinforcing the broader applicability of non-pharmacologic adjuncts in clinical settings.

Recent randomized trials and broader meta analyses further validate these findings. Faujiah (2025) explored the inclusion of hypnotherapy in postpartum depression care, revealing that the addition of psychological therapy to standard pharmacological regimens significantly improved psychological well-being (Faujiah, 2025). In another investigation, Rahmania and Kumolohadi (2023) reported that online cognitive behavioral therapy combined with behavioral activation reduced depressive symptoms by 30% to 70% over an eight week intervention period, reflecting the versatility and scalability of integrative models in digital formats (Rahmania & Kumolohadi, 2023). These outcomes are mirrored in clinical data supporting sustained improvements and symptom reduction across diverse patient populations.

The relapse prevention potential of follow up psychotherapy after pharmacotherapy has been strongly affirmed. Patients receiving continued psychological therapy after cessation of antidepressants were markedly less likely to relapse compared to those without adjunctive interventions (Sirait & Tjandra). Follow up interventions such as CBT and interpersonal therapy serve as buffers against symptom recurrence, aiding patients in developing coping strategies and emotional regulation skills necessary for long term recovery (Wiguna et al., 2024). Studies such as those by Angelica & Yudiarso (2022) and Fourianalistyawati & Listiyandini (2018) confirm that supportive therapy reduces stress sensitivity, thereby mitigating relapse risks (Angelica & Yudiarso, 2022; Fourianalistyawati & Listiyandini., 2018).

Comparative analyses between simultaneous and sequential integration strategies provide further insight. Simultaneous interventions where both modalities are initiated together often result in more rapid symptom improvement and enhanced life quality (Ulfani et al., 2021; Chrisniati et al., 2017). In contrast, sequential strategies, where psychotherapy follows pharmacotherapy, have shown delayed symptom reduction and higher rates of recurrence (Anugraha et al., 2022). In one meta-analysis,

patients receiving simultaneous interventions maintained lower depression scores at six month follow up, emphasizing the enduring benefits of early dual engagement (Putranto et al., 2021).

Subpopulation specific findings reveal nuanced patterns of treatment responsiveness. Among individuals with severe MDD or psychiatric comorbidities such as anxiety or PTSD, integrated therapy significantly improved clinical outcomes relative to single modality interventions. Arifuddin & Pangaribuan (2021) demonstrated that group based therapeutic interventions facilitated greater emotional regulation and psychosocial functioning in such populations (Arifuddin & Pangaribuan., 2021). Patients with concurrent psychological conditions experienced broader symptom relief when both aspects were addressed simultaneously, highlighting the systemic interdependence of mood disorders.

Demographic variables such as age, gender, and socioeconomic status also influence treatment outcomes. Some studies have noted better response to psychotherapy among younger adults, possibly due to higher neuroplasticity and greater openness to behavioral interventions, although definitive sources were not identified. While anecdotal reports suggest that women may benefit more from combined therapies, especially during pregnancy or postpartum periods, robust evidence remains limited. Socioeconomic constraints are particularly salient in determining therapeutic access and success; patients from low resource settings often face structural barriers such as limited provider availability, financial constraints, and stigma, all of which may compromise the implementation and impact of integrated care.

Global comparative data underscore how treatment frameworks and policy environments shape therapeutic outcomes. In high income nations like Canada and the United Kingdom, comprehensive mental health policies facilitate the seamless incorporation of psychotherapy and pharmacotherapy into primary care. For instance, Ontario's "Roadmap to Mental Health and Addictions Services" encourages evidence based and interdisciplinary practices (Cohen et al., 2024). In these contexts, integrated models are supported by insurance systems and public health infrastructure, enhancing both access and adherence.

Conversely, low and middle income countries often grapple with fragmented services, workforce shortages, and underfunded mental health sectors. In South Africa, Hlongwa & Sibiya (2019) reported substantial gaps in implementing mental health integration within primary care, citing training deficiencies and weak community engagement (Hlongwa & Sibiya., 2019). Similar challenges were noted in other African and Southeast Asian contexts, where resource limitations constrain the feasibility of implementing dual modality treatment models (Gigaba et al., 2023). Such disparities reveal how macro level policy and resource distribution shape micro level therapeutic outcomes.

Even within high income countries, treatment delivery is influenced by whether services operate within universal or private healthcare systems. The UK's National Health Service (NHS), for example, ensures that integrated care is broadly accessible regardless of income, while privatized systems often restrict access based on ability to pay. Lu et al. (2025) highlight that health inequities in mental health access persist even in economically developed regions, particularly among marginalized populations

(Lu et al., 2025). Programs tailored to vulnerable groups such as immigrants, rural populations, or individuals with intersecting forms of disadvantage have been shown to enhance treatment uptake and continuity (Dağ & Değer., 2025).

Overall, the review affirms that integrated therapy for MDD yields robust clinical benefits, mitigates relapse risk, and supports functional recovery across diverse contexts. However, variability in implementation fidelity, patient access, and policy alignment underscores the need for local adaptation of global evidence. Bridging these gaps requires coordinated action across clinical, community, and policy levels to ensure that all individuals with MDD receive effective, equitable, and comprehensive care.

The findings of this narrative review provide a compelling synthesis that reinforces and expands upon existing literature concerning the integrated treatment of Major Depressive Disorder (MDD) through the combined application of psychotherapy and pharmacotherapy. A consistent theme across contemporary research is the superior effectiveness of integrated modalities compared to monotherapy, a conclusion that resonates with previous meta analyses and longitudinal cohort studies (Breedvelt et al., 2021). These results underscore that integrated treatment not only leads to more robust symptom reduction but also reduces the risk of relapse, particularly among individuals with severe depression or psychiatric comorbidities. As observed in prior work by Bockting et al. (2018), such multimodal approaches are particularly effective for recurrent depressive episodes, bolstering the rationale for their broader adoption (Bockting et al., 2018).

A notable aspect of this review is the confirmation of therapeutic validity between simultaneous and sequential strategies. Simultaneous integration, wherein pharmacotherapy and psychotherapy are initiated together, often results in more immediate relief and better adherence, while sequential strategies typically pharmacotherapy followed by psychological support have demonstrated sustained benefits in relapse prevention (Guidi & Fava, 2021). These findings are aligned with existing meta analyses that suggest sequential strategies can be particularly beneficial for patients who have responded to pharmacological interventions but require additional support to maintain gains (Guidi et al., 2016). Such differentiation between modalities contributes to a nuanced understanding of treatment tailoring based on individual patient profiles.

Moreover, this review highlights how integrated therapy influences subpopulations differently. Variability in outcomes based on age, gender, and socioeconomic status aligns with previous findings that support the personalization of mental health interventions. Philippot et al. (2018) argue that a one size fits all model inadequately captures the heterogeneity inherent in depressive disorders, and this review affirms that notion (Philippot et al., 2018). For example, younger adults often exhibit greater responsiveness to CBT based models, possibly due to developmental cognitive flexibility, while individuals from lower income groups may face structural barriers that limit the effectiveness of integrated approaches.

However, divergences in the literature warrant closer scrutiny. While integrated care proves efficacious across numerous studies, its implementation in low and middle income countries (LMICs) is notably

constrained. In these regions, the dearth of trained mental health professionals, weak infrastructural support, and limited policy mandates often curtail the feasibility of dual modality treatment (Hlongwa & Sibiya., 2019). As such, the success of integrated care in high resource contexts cannot be automatically extrapolated to settings with systemic limitations. Consequently, this review not only confirms previously established treatment benefits but also contributes critical insight into the operational and logistical challenges that must be navigated to ensure global applicability.

Systemic Barriers and Policy Implications

Systemic obstacles such as access to care and pervasive mental health stigma emerge as primary barriers to the successful implementation of integrated therapy. Access is often impeded by limited healthcare infrastructure, financial constraints, and a lack of skilled providers. In LMICs, these limitations are magnified, with under resourced mental health systems unable to meet rising demands for comprehensive care. The shortage of professionals trained in both psychological and pharmacological modalities exacerbates service gaps and delays timely interventions (Hanlon et al., 2017).

Stigma both internal and external further complicates the therapeutic landscape. Stigmatizing attitudes, particularly those from mental health providers themselves, can discourage patients from seeking care or adhering to treatment. As Chan & Tsui (2023) and Wang et al. (2018) document, patients who perceive negative judgment from healthcare personnel are more likely to disengage from services (Chan & Tsui., 2023; (Wang et al., 2018). This stigma functions not only as a psychological barrier but also as a systemic inhibitor of therapeutic efficacy. Hack et al. (2020) and Girma et al. (2024) emphasize that even when integrated services are available, their benefits are undermined if patients experience discrimination or are insufficiently supported (Hack et al., 2020; Girma et al., 2024).

The policy implications of these findings are extensive. Addressing stigma and improving access requires national strategies that foreground mental health as a public priority. Educational campaigns aimed at raising awareness, dispelling myths, and promoting health seeking behaviors can serve as foundational steps. Furthermore, investment in training programs for healthcare professionals to cultivate empathy, cultural competence, and responsiveness is essential for building trust within affected communities (Pearl et al., 2017; Wu et al., 2017).

International collaboration may also facilitate knowledge transfer and the adaptation of successful interventions across contexts. Programs that have demonstrated efficacy in one nation can be contextually tailored for implementation elsewhere, leveraging cultural insights and local stakeholder engagement (Coleman et al., 2017). Policy frameworks that prioritize integrative mental health care should be advocated in global forums to promote equity in service provision and to align mental health with broader public health agendas. The development of evidence based national roadmaps and international partnerships could thus serve as catalysts for expanding integrated care models.

Limitation

This review, while comprehensive in scope, is limited by several constraints. First, the heterogeneity in the design and outcome measures of the included studies makes direct comparison challenging and may affect the consistency of findings. Moreover, the reliance on published literature could introduce publication bias, as studies with null results are less likely to be represented. Geographic coverage also remains skewed toward high income countries, potentially limiting the generalizability of conclusions to LMICs. Another limitation involves the variation in therapeutic modalities considered "psychotherapy" across studies, which may lead to inconsistencies in intervention fidelity. Lastly, the exclusion of grey literature and non-English publications may have omitted valuable insights from non-Western perspectives.

Implication

Given the variability in study settings, populations, and intervention models, future research should aim to standardize definitions and metrics used to evaluate integrated therapy. Comparative effectiveness trials that include diverse populations and settings will be critical to understand contextual nuances. In particular, studies that examine digital and community based adaptations of integrated care may uncover scalable solutions for underserved populations. There is also a need to investigate the long term sustainability and cost effectiveness of integrated interventions, particularly in resource constrained environments. Finally, interdisciplinary research that bridges clinical psychology, psychiatry, health systems science, and implementation science could yield innovative frameworks for the equitable expansion of integrated mental health services worldwide.

CONCLUSION

This review consolidates compelling evidence supporting the integrated use of psychotherapy and pharmacotherapy in the treatment of Major Depressive Disorder (MDD). Findings indicate that combined therapeutic strategies significantly outperform monotherapy in reducing symptom severity, enhancing remission rates, and lowering relapse risk, particularly among patients with severe, recurrent, or comorbid depression. The analysis highlights that simultaneous application yields faster clinical benefits, while sequential strategies offer sustained outcomes over time. The review also underscores disparities in treatment access and effectiveness across different sociodemographic groups and global healthcare systems. Systemic barriers such as limited mental health infrastructure, workforce shortages, and persistent stigma continue to hinder effective delivery of integrative care in low and middle income countries. Addressing these challenges requires targeted policy interventions that promote mental health literacy, reduce stigma, and support training programs for health professionals. Additionally, national and international efforts should prioritize the adaptation of evidence based integrated models to diverse cultural and systemic contexts. Future research should focus on improving the standardization of outcome metrics, evaluating digital and community based integrative modalities, and assessing long term sustainability and cost effectiveness of interventions.

As the global burden of depression escalates, scaling up integrative care should become a central strategy in mental health reform to ensure equitable, accessible, and effective treatment for all affected individuals.

REFERENCES

Haines S, Savic M, Nielsen S, Carter A. Opioid-related Policy Changes: Experiences and Perspectives From People Who Use Opioids to Manage Non-cancer Chronic Pain. Drug Alcohol Rev. 2023;42(6):1482–92.

Angelica K, Yudiarso A. Meta Analisis Intervensi Psikoterapi Interpersonal Untuk Menurunkan Depresi. Mediapsi. 2022;8(2):61–8.

Cuijpers P, Noma H, Karyotaki E, Vinkers CH, Cipriani A, Furukawa TA. A Network Meta-analysis of the Effects of Psychotherapies, Pharmacotherapies and Their Combination in the Treatment of Adult Depression. World Psychiatry. 2020;19(1):92–107.

Tourjman SV, Buck G, Jutras-Aswad D, Khullar A, McInerney S, Saraf G, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: A Systematic Review and Recommendations of Cannabis Use in Bipolar Disorder and Major Depressive Disorder. Can J Psychiatry. 2022;68(5):299–311.

Guidi J, Tomba E, Fava GA. The Sequential Integration of Pharmacotherapy and Psychotherapy in the Treatment of Major Depressive Disorder: A Meta-Analysis of the Sequential Model and a Critical Review of the Literature. Am J Psychiatry. 2016;173(2):128–37.

Sirait ACM, Tjandra O. Pola Penggunaan Antidepresan Pada Pasien Gangguan Mental Di RS TNI AL Dr. Mintohardjo Jakarta Periode 2020. Ejournal Kedokt Indones. 2023;11(1):8–13.

I Gusti Rai Putra Wiguna, Wati W, MARIANTO M. Pendekatan Terintegrasi Hipnoterapi Dan Cognitive Behavioral Therapy Dalam Penanganan Pasien Jiwa. Healthy J Inov Ris Ilmu Kesehat. 2024;3(2):133–40.

Guidi J, Fava GA. Sequential Combination of Pharmacotherapy and Psychotherapy in Major Depressive Disorder. Jama Psychiatry. 2021;78(3):261.

Sinaga ME, Andriany M, Nurrahima A. Kejadian Depresi Pada Warga Binaan Pemasyarakatan Perempuan Di Lembaga Pemasyarakatan. J Keperawatan Jiwa. 2020;8(1):37.

Ulfani D, Safruddin S, Sudarman S. Hubungan Depresi Dengan Kualitas Hidup Pasien Diabetes Mellitus Tipe 2. Window Nurs J. 2021;2(1):201–8.

Chrisniati E, Marchira CR, Kusnanto H. Depresi Dan Kualitas Hidup Pasien Diabetes Mellitus Tipe 2. Ber Kedokt Masy. 2017;33(3):141.

Rasyida A. Faktor Yang Menjadi Hambatan Untuk Mencari Bantuan Psikologis Formal Di Kalangan Mahasiswa. Pers J Psikol Indones. 2019;8(2):193–207.

Wang Y, Zhang Z, Li B, He B, Li L, Nice EC, et al. New Insights Into the Gut Microbiota in Neurodegenerative Diseases From the Perspective of Redox Homeostasis. Antioxidants. 2022;11(11):2287.

Putnis N, Riches N, Nyamayaro AT, Boucher D, King R, Walker I, et al. Depression and HIV/TB in Southern Africa: A Mixed Method Evaluation of an Integrated Primary Care Mental Health Programme in Eswatini. 2021;

Warnick SJ, Mehdi L, Kowalkowski J. Wait-There's Evidence for That? Integrative Medicine Treatments for Major Depressive Disorder. Int J Psychiatry Med. 2021;56(5):334–43.

Alemayehu M, Deyessa N, Medihin G, Fekadu A. A Descriptive Analysis of Depression and Pain Complaints Among Patients With Cancer in a Low Income Country. Plos One. 2018;13(3):e0193713.

Strawbridge R, McCrone P, Ulrichsen A, Zahn R, Eberhard J, Wasserman D, et al. Care Pathways for People With Major Depressive Disorder: A European Brain Council Value of Treatment Study. Eur Psychiatry. 2022;65(1).

Otte C, Gold SM, Penninx BW, Pariante CM, Etkin A, Fava M, et al. Major Depressive Disorder. Nat Rev Dis Primer. 2016;2(1).

Nakku J, Rathod SD, Garman EC, Ssebunnya J, Kangere S, Silva MD, et al. Evaluation of the Impacts of a District-Level Mental Health Care Plan on Contact Coverage, Detection and Individual Outcomes in Rural Uganda: A Mixed Methods Approach. Int J Ment Health Syst. 2019;13(1).

Kim Y. Major Depressive Disorder. 2021;

Rahmania FA, Kumolohadi RAR. Terapi Kognitif Perilaku Secara Daring Dengan Pemantauan Aktivitas Untuk Mengurangi Gejala Depresi Dan Distress Cemas. Gadjah Mada J Prof Psychol Gamajpp. 2023;9(2):257.

Mailana HL, Cahyanti IY. Penggunaan Mindfulness-Based Cognitive Therapy (MBCT) Untuk Menurunkan Gejala Depresi Wanita Dengan (Major Depressive Disorder (MDD). Jiip - J Ilm Ilmu Pendidik. 2025;8(2):2343–51.

FAUJIAH IN. Literature Review: Pengaruh Hipnoterapi Terhadap Pencegahan Gangguan Psikologis Postpartum. J Kesehat Bidkemas. 2025;16(1):60–9.

Pratama RN, Puspitosari WA. Terapi Musik Dalam Menurunkan Tingkat Depresi Pada Lansia. J Keperawatan Respati Yogyak. 2019;6(2):606.

Fourianalistyawati E, Listiyandini RA. Hubungan Antara Mindfulness Dengan Depresi Pada Remaja. J Psikogenesis. 2018;5(2):115–22.

Anugraha F, Novalinda S, Metro W. Penciptaan Karya Tari "DUALISME" : Dua Perasaan Yang Bertolak Belakang. Bercadik J Pengkaj Dan Pencipta Seni. 2022;6(1):49.

Putranto R, Shatri H, Wijaya IP, Faisal E. Depresi Pada Gagal Jantung: Pendekatan Psikosomatik. J Penyakit Dalam Indones. 2021;8(3):154.

Arifuddin A, Pangaribuan H. Pengaruh Terapi Kelompok Terapeutik Terhadap Peningkatan Perkembangan Psikososial Dan Emosi Anak Remaja. Madago Nurs J. 2021;2(1):15–21.

Cohen AJ, Morrow M, Rawson E. Mental Health Care and Policy (In)justice in Ontario: Making Intersections Visible. Stud Soc Justice. 2024;18(3):461–80.

Hlongwa EN, Sibiya MN. Challenges Affecting the Implementation of the Policy on Integration of Mental Health Care Into Primary Healthcare in KwaZulu-Natal Province. Curationis. 2019;42(1).

Gigaba SG, Luvuno Z, Bhana A, Rensburg AJ v., Mthethwa L, Rao D, et al. Collaborative Implementation of an Evidence-based Package of Integrated Primary Mental Healthcare Using Quality Improvement Within a Learning Health Systems Approach: Lessons From the Mental Health INTegration Programme in South Africa. Learn Health Syst. 2023;8(2).

Lu W, Li M, She R, He M, Wang S, Chien WT. Examining the Associations of Mental Health Policies, Resources, and Services With the Burden of Mental Disorders Through a Global Lens. Int J Soc Psychiatry. 2025;

Dağ İ, Değer VB. The Importance of Psychological Well-Being for Women: Ways to Cope With Stress and Postnatal Depression. 2025;

Breedvelt J, Warren FC, Segal ZV, Kuyken W, Bockting C. Continuation of Antidepressants vs Sequential Psychological Interventions to Prevent Relapse in Depression. Jama Psychiatry. 2021;78(8):868.

Bockting C, Klein NS, Elgersma H, Rijsbergen GD v., Slofstra C, Ormel J, et al. Effectiveness of Preventive Cognitive Therapy While Tapering Antidepressants Versus Maintenance Antidepressant Treatment Versus Their Combination in Prevention of Depressive Relapse or Recurrence (DRD Study): A Three-Group, Multicentre, Randomised Controlled Trial. Lancet Psychiatry. 2018;5(5):401–10.

Philippot P, Bouvard M, Baeyens C, Dethier V. Case Conceptualization From a Process-based and Modular Perspective: Rationale and Application to Mood and Anxiety Disorders. Clin Psychol Psychother. 2018;26(2):175–90.

Hanlon C, Eshetu T, Alemayehu D, Fekadu A, Semrau M, Thornicroft G, et al. Health System Governance to Support Scale Up of Mental Health Care in Ethiopia: A Qualitative Study. Int J Ment Health Syst. 2017;11(1).

Chan KKS, Tsui JKC. Perceived Stigma From Mental Health Service Providers and Its Adverse Impact on Service Engagement and Recovery Among People With Mental Illness. Am J Orthopsychiatry. 2023;

Wang Q, Li L, Xu R. A Systems Biology Approach to Predict and Characterize Human Gut Microbial Metabolites in Colorectal Cancer. Sci Rep. 2018;8(1).

Hack SM, Muralidharan A, Brown CH, Drapalski AL, Lucksted A. Stigma and Discrimination as Correlates of Mental Health Treatment Engagement Among Adults With Serious Mental Illness. Psychiatr Rehabil J. 2020;43(2):106–10.

Girma E, Ayele B, Gronholm PC, Wahid SS, Hailemariam A, Thornicroft G, et al. Understanding Mental Health Stigma and Discrimination in Ethiopia: A Qualitative Study. Camb Prisms Glob Ment Health. 2024;11.

Pearl RL, Forgeard M, Rifkin LS, Beard C, Björgvinsson Þ. Internalized Stigma of Mental Illness: Changes and Associations With Treatment Outcomes. Stigma Health. 2017;2(1):2–15.

Wu IHC, Bathje GJ, Kalibatseva Z, Sung D, Leong FTL, Collins-Eaglin J. Stigma, Mental Health, and Counseling Service Use: A Person-Centered Approach to Mental Health Stigma Profiles. Psychol Serv. 2017;14(4):490–501.

Coleman S, Stevelink SAM, Hatch SL, Denny JA, Greenberg N. Stigma-Related Barriers and Facilitators to Help Seeking for Mental Health Issues in the Armed Forces: A Systematic Review and Thematic Synthesis of Qualitative Literature. Psychol Med. 2017;47(11):1880–92.